Mirum Pharmaceuticals (MIRM) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Mirum Pharmaceuticals (MIRM) overview

Mirum Pharmaceuticals (MIRM) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 521m and operating profit of USD -22.1m; the year-end share price was 78.99 USD and market capitalisation was USD 4,099m. Mirum Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Mirum Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 315mFY 2025
Share price78.99 USDFY 2025 year end
RevenueUSD 521mFY 2025
Operating profitUSD -22.1mFY 2025
Net earningsUSD -23.4mFY 2025
Market capitalisationUSD 4,099mFY 2025 year end

About Mirum Pharmaceuticals

Mirum Pharmaceuticals develops and commercializes medicines for rare diseases. Its commercial portfolio includes Livmarli for Alagille syndrome and progressive familial intrahepatic cholestasis; ATEBRIOZ for fibrodysplasia ossificans progressiva; and Cholbam and Ctexli for specified bile-acid disorders. Its pipeline includes volixibat for cholestatic liver diseases, brelovitug for chronic hepatitis delta, and MRM-3379 for fragile X syndrome.

Generate the Mirum Pharmaceuticals report

Mirum Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Mirum Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Mirum Pharmaceuticals

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.